Respiratory Disease Vaccine Market Introduction and Overview
According to SPER Market Research, the Global Respiratory Disease Vaccine Market is estimated to reach USD 109.49 billion by 2034 with a CAGR of 1.44%.
The report includes an in-depth analysis of the Global Respiratory Disease Vaccine Market, including market size and trends, Interface mix, Applications, and supplier analysis. The introduction of respiratory disease vaccinations has been critical in managing illnesses such as influenza, COVID-19, pneumonia, and RSV, resulting in considerable reductions in morbidity and mortality worldwide. Rising respiratory infection rates, growing immunization awareness, improvements in vaccine technology (such as mRNA and recombinant vaccines), and robust government initiatives supporting mass vaccination campaigns are the main factors driving the market for these vaccines. Demand is also fueled by the aging population and people with long-term illnesses. High R&D expenses, rigorous regulatory approval procedures, vaccine hesitancy, and distribution logistical obstacles particularly in low-income areas remain obstacles, nevertheless. Notwithstanding these challenges, it is anticipated that ongoing innovation, public-private partnerships, and enhanced cold chain logistics will propel the market ahead.
By Type Insights: Based on Type the market is divided into three segments: Viral Vaccine, Bacterial Vaccine and Combination Vaccine. The viral vaccine segment had the greatest market share in 2024, owing to the rise in viral respiratory disorders such as influenza, respiratory syncytial virus (RSV), and coronavirus infections. For example, the CDC estimates that there will be 27 million influenza cases in May 2023, which will result in 19,000 fatalities in the United States. Additionally, the creation and approval of vaccines have been made easier by cooperation between regulatory bodies, research institutes, and vaccine makers.
By Age Group Insights: Based on Age Group the market is divided into two segments: Pediatric and Adult. In 2024, the market for respiratory disease vaccines was dominated by the adult segment. The increasing incidence of respiratory disorders in the adult population is responsible for the segment's growth. As the world's population ages, a greater percentage of elderly persons are at higher risk of respiratory infections and associated sequelae. As a result, there is now more focus on immunization campaigns aimed at this age group, including the creation and marketing of adult-specific vaccines. Additionally, it is projected that the growing adult population's understanding of the value of vaccinations will fuel segment expansion.
By Infection Insights: Based on Infection the market is divided into five segments: COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia and Others. In 2024, the COVID-19 category dominated the market for respiratory disease vaccines. The international scientific community has quickly created and approved a number of COVID-19 vaccines in response to growing worries about stopping the spread of SARS-CoV-2 infection. The purpose of their approval was to prevent the transmission of viruses. Many vaccines were created, such as the inactivated vaccine by SINOVAC and Bharat Biotech, the viral vector vaccine by AstraZeneca and Johnson & Johnson, and the mRNA-based vaccine by Pfizer-BioNTech and Moderna.
By Distribution Channel Insights: Based on Distribution Channel the market is divided into three segments: Hospital & Retail Pharmacies, Government Suppliers and Others. In 2024, the hospital and retail pharmacies segment held the highest share, owing to the increased prevalence of respiratory disorders in the population. Dedicated medical staff, including physicians and nurses, who have received vaccination training, including respiratory vaccinations, work in hospitals. They offer immunization services to patients in hospital settings, especially those who are more susceptible to respiratory illnesses, like the elderly or people with underlying medical issues. Additionally, walk-in vaccination programs are frequently offered by retail pharmacies, enabling people to get respiratory immunizations without an appointment.
By Regional Insights: Asia Pacific had the greatest market share in 2024 and is predicted to hold this position throughout the forecast period. The rising prevalence of respiratory illnesses, expanding government programs, and an aging population are all contributing factors to the region's market expansion. The population of the area is aging quickly, making them vulnerable to respiratory illnesses like influenza and pneumonia. Immunization has been essential in preventing serious consequences for the elderly and lessening the strain on healthcare systems.
Market Competitive Landscape:
The market for Respiratory Disease Vaccine is quite competitive. In order to increase the range of services and products they offer, companies in the Respiratory Disease Vaccine market are working with regional players and going worldwide. Some of the prominent players in Global Respiratory Disease Vaccine Market are AstraZeneca, Bavarian Nordic, EMERGENT, GSK plc, INOVIO Pharmaceuticals, Johnson & Johnson Services Inc, Merck & Co. Inc, Moderna Inc, Novavax and Pfizer Inc.
Recent Developments:
- In May 2024, Sanofi and Novavax signed a co-exclusive licensing contract to jointly develop new flu-COVID-19 combination vaccines and co-commercialize Novavax's adjuvanted COVID-19 vaccine. This strategic alliance might increase Sanofi's long-term vaccine sales, broaden its vaccine portfolio, and solidify its place in the post-pandemic vaccine market.
- In October 2023, Modern Inc. declared that the first patient in the phase III research of its combination vaccine candidate, mRNA-1083, which targets both influenza and COVID-19, had been dosed in the United States, marking a significant milestone. Since mRNA-1083 is Moderna's first respiratory combination vaccine candidate to move forward to a phase III study, this is a calculated step. This calculated move could establish Moderna as a pioneer in the creation of innovative vaccinations against respiratory illnesses.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Type, By Age Group, By Infection, By Distribution Channel. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | AstraZeneca, Bavarian Nordic, EMERGENT, GSK plc, INOVIO Pharmaceuticals, Johnson & Johnson Services Inc, Merck & Co. Inc, Moderna Inc, Novavax, Pfizer Inc. and others. |
Key Topics Covered in the Report:
- Global Respiratory Disease Vaccine Market Size (FY’2021-FY’2034)
- Overview of Global Respiratory Disease Vaccine Market
- Segmentation of Global Respiratory Disease Vaccine Market By Type (Viral Vaccine, Bacterial Vaccine and Combination Vaccine)
- Segmentation of Global Respiratory Disease Vaccine Market By Age Group (Pediatric and Adult)
- Segmentation of Global Respiratory Disease Vaccine Market By Infection (COVID-19, Influenza, Respiratory Syncytial Virus, Pneumonia and Others)
- Segmentation of Global Respiratory Disease Vaccine Market By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others)
- Statistical Snap of Global Respiratory Disease Vaccine Market
- Expansion Analysis of Global Respiratory Disease Vaccine Market
- Problems and Obstacles in Global Respiratory Disease Vaccine Market
- Competitive Landscape in the Global Respiratory Disease Vaccine Market
- Details on Current Investment in Global Respiratory Disease Vaccine Market
- Competitive Analysis of Global Respiratory Disease Vaccine Market
- Prominent Players in the Global Respiratory Disease Vaccine Market
- SWOT Analysis of Global Respiratory Disease Vaccine Market
- Global Respiratory Disease Vaccine Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Respiratory Disease Vaccine Market Manufacturing Base Distribution, Sales Area, Interface Type
6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Respiratory Disease Vaccine Market
7. Global Respiratory Disease Vaccine Market, By Type (USD Million) 2021-2034
7.1. Viral Vaccine
7.2. Bacterial Vaccine
7.3. Combination Vaccine
8. Global Respiratory Disease Vaccine Market, By Age Group (USD Million) 2021-2034
8.1. Pediatric
8.2. Adult
9. Global Respiratory Disease Vaccine Market, By Infection (USD Million) 2021-2034
9.1. COVID-19
9.2. Influenza
9.3. Respiratory Syncytial Virus (RSV)
9.4. Pneumonia
9.5. Others
10. Global Respiratory Disease Vaccine Market, By Distribution Channel (USD Million) 2021-2034
10.1. Hospital & Retail Pharmacies
10.2. Government Suppliers
10.3. Others
11. Global Respiratory Disease Vaccine Market, (USD Million) 2021-2034
11.1. Global Respiratory Disease Vaccine Market Size and Market Share
12. Global Respiratory Disease Vaccine Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3. India
12.1.4. Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5. United Kingdom
12.2.6. Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. AstraZeneca
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Interface summary
13.1.4. Recent developments
13.2. Bavarian Nordic
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Interface summary
13.2.4. Recent developments
13.3. EMERGENT
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Interface summary
13.3.4. Recent developments
13.4. GSK plc
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Interface summary
13.4.4. Recent developments
13.5. INOVIO Pharmaceuticals
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Interface summary
13.5.4. Recent developments
13.6. Johnson & Johnson Services Inc
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Interface summary
13.6.4. Recent developments
13.7. Merck & Co. Inc
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Interface summary
13.7.4. Recent developments
13.8. Moderna Inc
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Interface summary
13.8.4. Recent developments
13.9. Novavax
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Interface summary
13.9.4. Recent developments
13.10. Pfizer Inc
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Interface summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links